Coeptis Therapeutics Plans To Pursue DVX201, Its Proprietary Allogeneic Stem Cell Expansion And Directed Differentiation Platform Of Unmodified Natural Killer Cell Therapy, As An Antiviral Treatment Addressing Various Respiratory Viral Infections

2/7/24 7:40:46 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $COEP alert in real time by email

Get the next $COEP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COEP

Date	Price Target	Rating	Analyst

More analyst ratings

$COEP
Press Releases

Fastest customizable press release news feed in the world

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities WEXFORD, Pa., Nov. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that results from their Phase 1 st
11/7/24 8:07:00 AM ET
$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
WEXFORD, Pa., Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology. This expansion includes the use of unmodified NK cells in treating viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
10/24/24 8:07:00 AM ET
$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy
WEXFORD, Pa., Oct. 15, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced that its Chief Scientific and Medical Officer Colleen Delaney, MD will attend and present at the following upcoming fall conferences. These events, including the 2024 AABB Annual Meeting, the 50th ASHI Annual Meeting, the Advanced Therapies USA Congress, and the Donor Selection & Cell Source Summit, offer an opportunity to expand awareness of Coeptis' advancements in universal cell therapy and its potential to transform patient outcomes.
10/15/24 8:07:00 AM ET
$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$COEP
Market Insights

Live Market Insights

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 30.78% to $5.99. The market value of their outstanding shares is at $29.3 million. Rezolute (NASDAQ:RZLT) shares rose 25.0% to $3.75. The company's market cap stands at $150.5 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 16.26% to $1.0. The market value of their outstanding shares is at $146.6 million. Coeptis Therapeutics (NASDAQ:COEP) shares increased by 15.72% to $0.39. The company's market cap stands at $14.4 million. Qilian Intl Hldg Gr
5/22/24 8:06:41 AM ET
$AHG
$CING
$COEP
$DMTK
Business Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Coeptis Therapeutics To Present Universal Allogeneic SNAP-CAR NK Cell Therapy At ISCT 2024 From May 28 To June 1
5/8/24 8:56:40 AM ET
$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197
4/4/24 4:31:22 PM ET
$ACOR
$AIH
$ANTX
$CADL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medical Specialities
Biotechnology: Pharmaceutical Preparations

Coeptis Therapeutics Plans To Pursue DVX201, Its Proprietary Allogeneic Stem Cell Expansion And Directed Differentiation Platform Of Unmodified Natural Killer Cell Therapy, As An Antiviral Treatment Addressing Various Respiratory Viral Infections

Chat with this insight

Recent Analyst Ratings for
$COEP

$COEP
Press Releases

Fastest customizable press release news feed in the world

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

$COEP
Leadership Updates

Live Leadership Updates

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

$COEP
Financials

Live finance-specific insights

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

$COEP
SEC Filings

SEC Form DEF 14A filed by Coeptis Therapeutics Holdings Inc.

SEC Form 10-Q filed by Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$COEP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

$COEP
Market Insights

Live Market Insights

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Coeptis Therapeutics To Present Universal Allogeneic SNAP-CAR NK Cell Therapy At ISCT 2024 From May 28 To June 1

12 Health Care Stocks Moving In Thursday's After-Market Session

Coeptis Therapeutics Plans To Pursue DVX201, Its Proprietary Allogeneic Stem Cell Expansion And Directed Differentiation Platform Of Unmodified Natural Killer Cell Therapy, As An Antiviral Treatment Addressing Various Respiratory Viral Infections

Chat with this insight

Recent Analyst Ratings for $COEP

$COEP Press Releases

Fastest customizable press release news feed in the world

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

$COEP Leadership Updates

Live Leadership Updates

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

$COEP Financials

Live finance-specific insights

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

$COEP SEC Filings

SEC Form DEF 14A filed by Coeptis Therapeutics Holdings Inc.

SEC Form 10-Q filed by Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$COEP Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

$COEP Market Insights

Live Market Insights

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Coeptis Therapeutics To Present Universal Allogeneic SNAP-CAR NK Cell Therapy At ISCT 2024 From May 28 To June 1

12 Health Care Stocks Moving In Thursday's After-Market Session

Recent Analyst Ratings for
$COEP

$COEP
Press Releases

$COEP
Leadership Updates

$COEP
Financials

$COEP
SEC Filings

$COEP
Large Ownership Changes

$COEP
Market Insights